Castle Biosciences Inc’s recent filing unveils that its Pres. & Chief Exec. Officer MAETZOLD DEREK J unloaded Company’s shares for reported $94851.0 on Apr 21 ’25. In the deal valued at $21.52 per share,4,408 shares were sold. As a result of this transaction, MAETZOLD DEREK J now holds 4,275 shares worth roughly $79258.5.
Then, MAETZOLD DEREK J sold 1,236 shares, generating $26,596 in total proceeds. Upon selling the shares at $21.52, the Pres. & Chief Exec. Officer now owns 74,627 shares.
Before that, MAETZOLD DEREK J sold 3,647 shares. Castle Biosciences Inc shares valued at $73,739 were divested by the Pres. & Chief Exec. Officer at a price of $20.22 per share. As a result of the transaction, MAETZOLD DEREK J now holds 4,440 shares, worth roughly $82317.59999999999.
Guggenheim initiated its Castle Biosciences Inc [CSTL] rating to a Buy in a research note published on December 14, 2023; the price target was $25. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Stephens began covering CSTL with “an Overweight” recommendation on January 07, 2022. Lake Street started covering the stock on April 30, 2021. It rated CSTL as “a Buy”.
Price Performance Review of CSTL
On Tuesday, Castle Biosciences Inc [NASDAQ:CSTL] saw its stock fall -3.79% to $18.54. Over the last five days, the stock has gained 2.77%. Castle Biosciences Inc shares have fallen nearly -30.43% since the year began. Nevertheless, the stocks have fallen -18.25% over the past one year. While a 52-week high of $35.84 was reached on 01/08/25, a 52-week low of $15.45 was recorded on 05/28/25.
Levels Of Support And Resistance For CSTL Stock
The 24-hour chart illustrates a support level at 17.96, which if violated will result in even more drops to 17.38. On the upside, there is a resistance level at 19.24. A further resistance level may holdings at 19.94.
The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $70 price target.
